Elizabeth King, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1629161500
Payments from drug & device makers
Across 539 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$4K
- Tandem Diabetes Care, Inc.$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- Medtronic$881
- Amgen$784
- plus $7K from 50 others
What the payments were for
- Consulting fees$3,00018%
- Speaking & faculty fees$1,4509%
- Travel & lodging$8955%
- Food & beverage$11,44068%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$3,895
- t:slim X2 insulin pump$1,100
- t-slim insulin pump$350
- FARXIGA$228
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$226
- Resolute$175
- SYMPLICITY G3$161
- APOLLOTM$147
- Veozah$137
- CRENESSITY$134
- MYCAPSSA$121
How this compares
$16,785 in reported general payments places this provider in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $133,445 |
| MounjaroTirzepatide | 52 | $67,447 |
| JanuviaSitagliptin Phosphate | 31 | $37,458 |
| RybelsusSemaglutide | 23 | $34,140 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $26,703 |
| JardianceEmpagliflozin | 21 | $24,772 |
| FarxigaDapagliflozin Propanediol | 20 | $23,186 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $11,813 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $10,138 |
| Novolog FlexpenInsulin Aspart | 26 | $7,881 |
| SynthroidLevothyroxine Sodium | 91 | $6,587 |
| HumalogInsulin Lispro | 22 | $6,281 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 11 | $4,547 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 29 | $3,158 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $2,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,250 | $167,585101 claims |
| Lilly USA, LLCMounjaro, Humalog | $400 | $73,72874 claims |
| Boehringer IngelheimJardiance | $238 | $24,77221 claims |
| AstraZenecaFarxiga | $1,195 | $23,18620 claims |
| AbbVieSynthroid | $256 | $6,58791 claims |
| Cequr CorporationCequr Simplicity | $22 | $4,54711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $117 | $1,515153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.